Humacyte registers two Symvess trials: adolescent Phase 3 study and adult Phase 4 real-world study

This week's registry activity centers on Humacyte, Inc. and its product Symvess, with two new trial listings, both marked not yet recruiting.

• **Phase 3, adolescents with extremity arterial injury (NCT07762313):** The study is designed to assess the safety and efficacy of SYMVESS as a vascular conduit for repair of extremity arterial injury in adolescents age 17 years or younger who have reached adult sexual maturity, Tanner Sexual Maturity Rating Stage 5, in patients who require urgent revascularization to avoid imminent limb loss and for whom autologous vein graft is not feasible.¹ The trial has an estimated enrollment of 10 participants¹, with a primary completion date estimated for 2028-12.
• **Phase 4, adult post-marketing observational study (NCT07762794):** This study is meant to further assess the long-term safety and efficacy of Symvess in a real-world setting in adult patients with extremity arterial injury.² Its primary objective is to determine Symvess secondary patency at 1 year², with an estimated enrollment of 125 participants and a primary completion date estimated for 2030-09.